Study of Octaplex dosing accuracy: an in vitro analysis

Area of Science:

• Hematology
• Pharmacology

Background:

• Prothrombin complex concentrates (PCC) are crucial for urgent warfarin reversal.
• Optimal PCC dosing strategies, fixed versus weight-based, remain debated.

Purpose of the Study:

• To evaluate the in vitro impact of different prothrombin complex concentrate (PCC) doses on international normalized ratio (INR) and clotting factor activity.
• To compare fixed-dose versus weight-based dosing for warfarin reversal.

Main Methods:

• Plasma from warfarin-anticoagulated patients was treated with 1,000, 2,000, or 3,000 IU of PCC in vitro.
• International normalized ratio (INR) and specific clotting factor (II, VII, IX, X) activities were measured before and after PCC administration.
• Weight-based dosing effects were estimated.

Main Results:

• A fixed dose of 1,000 IU PCC corrected INR to below 1.5, with further decreases at higher doses.
• Clotting factors II, VII, and X activities increased with higher PCC doses, showing linear correlation with INR.
• Factor IX activity did not consistently increase or correlate with INR reversal.
• Estimated weight-based dosing achieved INRs below 1.2 and factor activities above 0.50 IU for factors II, VII, and X, but Factor IX correction was variable.

Conclusions:

• While 1,000 IU PCC corrects INR, higher doses are needed for uniform factor activity correction (>0.50 IU with 2,000 IU, >1.00 IU with 3,000 IU).
• INR normalization alone may not fully reflect adequate clotting factor levels.
• These in vitro findings support the potential benefit of weight-based dosing for more precise warfarin reversal.